By Lauren Weber and Christina Jewett March 17, 2020

The two top makers of the highly specialized swabs used to test patients for the novel coronavirus are straining to keep up with the demand, even as both the Italian and U.S. governments are working with them to increase production, including at a key manufacturing site in the midst of Italy’s outbreak.

The nasopharyngeal swabs required for the coronavirus tests are quite different from your standard Q-tips — and the exploding need for them has created a bottleneck in the soaring demand for diagnoses.

The swabs have to be long and skinny enough to get to the nasopharynx, the upper part of the throat, behind the nose. They must be made of synthetic fiber and cannot have a wooden shaft. Nor can they contain calcium alginate, a substance typically used for swab tips in wound care, as that can kill the virus, according to the Centers for Disease Control and Prevention.

These swabs are currently singled out by CDC and Food and Drug Administration guidelines as suitable for most coronavirus testing. Once used, they’re typically mailed in transportable vials full of a solution known as “viral transport media,” which keeps the virus testable.

While last week’s critical shortage was a reagent chemical used in the diagnostic tests, now the specialized swabs are in dire demand, according to Soumi Saha, a pharmacist who is the senior director of advocacy for Premier Inc., a group purchasing organization that procures supplies for 4,000 U.S. hospitals and health systems. As testing finally ramps up in the U.S., hospitals especially are having a hard time getting enough of these swabs, Saha said.

Subscribe to KHN's free Morning Briefing.

“We have folks that can’t get a hand on any of them right now,” Saha said. “Hospitals want to do their part and want to expand access to testing, but they’re hamstrung by the fact that they can’t access the actual swabs.”

Former FDA commissioner Scott Gottlieb pointed out on Twitter on Monday that a lack of swabs could be the new bottleneck even as the number of sites with the capacity to test has increased, showcasing that the weakest link in the supply chain becomes the limiting factor.

Missouri has been among the places seeing a shortage of swabs, state Department of Health and Senior Services spokesperson Lisa Cox confirmed over the weekend. Ontario, Canada, plus counties in Washington and Michigan have announced that limitations on swabs were creating a logjam in their testing capabilities, according to news reports. Axios first reported on the national swab shortages last week.

Part of the problem lies in the nature of current test procedures for COVID-19. Typically, one needs to use two swabs per person: one swab for a flu test to potentially rule out the need for a coronavirus test, then another for the coronavirus if the flu test is negative.

Since the swabs are a product that is regulated, patented and specialized, they’re hard to make on the fly, Saha said. That puts additional pressure on the two largest manufacturers.

One of them, Puritan Medical Products, based in Guilford, Maine, has been working to keep up with demand even as its workforce, like many in America, has been affected by the spread of the virus, spokesperson Timothy Templet said.

The U.S. Department of Health and Human Services, along with working groups from the White House and other federal agencies, has been in discussion with the company over the past week to redirect some of their manufacturing capabilities away from other clients to COVID-19 specialty swab production, Templet said.

Currently, Templet estimated, Puritan is producing between 800,000 and a million swabs a week that could go to COVID-19 efforts. If the government decides to redirect its manufacturing efforts, cutting off the supply of its other medical products for items like flu kits, it could make millions more.

Still, Templet said that ramping up production so drastically would take a few weeks to get fully off the ground, considering manufacturing capabilities and protocols.

Templet said HHS plans to open 37 testing sites across the country in the coming days to account for increased testing needs — which will require even more specialty swabs. He also said the government is considering expanding its recommended testing material options to allow for more general nasal swabs to keep up with the increased testing demand.

FDA spokesperson Stephanie Caccomo said in an email that the agency is aware of “supply chain pressures on obtaining certain materials for running tests” and that it is continuing to evaluate other options for specimen collection supplies, which it will list on its website.

Another specialty swab manufacturer, Copan Diagnostics Inc., which is based in the Lombardy region of northern Italy, is working 24/7 in a “tremendous effort” to produce products such as its CDC-recommended and patent-protected FLOQSwabs, all while asking customers and distributors to ration orders to maximize output, spokesperson Gabriela Franco said in an email.

While produced in a region hit hard by the novel coronavirus, where most other work has stopped, Franco said, the Italian government has allowed the business to continue production. And it is working with local and national authorities on keeping production up in case stricter health restrictions are adopted.

Copan could produce 720,000 specialized swabs in a day and as many as 100 million per year for the global market, according to records the firm filed in a 2018 patent lawsuit.

Amid the crunch, Copan CEO Stefania Triva said in an emailed statement that her company is working round-the-clock to keep up with demand.

“Without full commitment and sacrifices from all of my staff, we would not be able to meet this unexpected demand,” Triva said. “COPAN’s more than 660 members of staff, many of whom are women, without hesitation, once made aware of the Coronavirus emergency, have stepped up from five working days and two shifts to seven working days and night shifts also.”

The volume of Copan swabs arriving in the U.S. has been increasing, according to data from Import Genius, which tracks container ships arriving in American ports. Six tons of Copan culture swabs arrived at the port of Norfolk, Virginia, on March 4. Before that, 4.5 tons of swabs arrived at the same port on Jan. 20. The swabs then tend to go to domestic test-kit assemblers that package them for health care use.

New Jersey-based Becton, Dickinson and Co., a leading assembler of those kits involved in ramping up coronavirus testing, has seen extremely high demand for swab products this year, company spokesperson Troy Kirkpatrick said. But now that Copan is “running operations 24/7” to increase production, Kirkpatrick said, “we will be providing hundreds of thousands of swabs to the U.S. market each week.”

Lauren Weber: LaurenW@kff.org, @LaurenWeberHP

Christina Jewett: ChristinaJ@kff.org, @by_cjewett

We want to hear from you: Contact Us

By Lauren Weber and Christina Jewett March 17, 2020

The two top makers of the highly specialized swabs used to test patients for the novel coronavirus are straining to keep up with the demand, even as both the Italian and U.S. governments are working with them to increase production, including at a key manufacturing site in the midst of Italy’s outbreak.

The nasopharyngeal swabs required for the coronavirus tests are quite different from your standard Q-tips — and the exploding need for them has created a bottleneck in the soaring demand for diagnoses.

The swabs have to be long and skinny enough to get to the nasopharynx, the upper part of the throat, behind the nose. They must be made of synthetic fiber and cannot have a wooden shaft. Nor can they contain calcium alginate, a substance typically used for swab tips in wound care, as that can kill the virus, according to the Centers for Disease Control and Prevention.

These swabs are currently singled out by CDC and Food and Drug Administration guidelines as suitable for most coronavirus testing. Once used, they’re typically mailed in transportable vials full of a solution known as “viral transport media,” which keeps the virus testable.

While last week’s critical shortage was a reagent chemical used in the diagnostic tests, now the specialized swabs are in dire demand, according to Soumi Saha, a pharmacist who is the senior director of advocacy for Premier Inc., a group purchasing organization that procures supplies for 4,000 U.S. hospitals and health systems. As testing finally ramps up in the U.S., hospitals especially are having a hard time getting enough of these swabs, Saha said.

Subscribe to KHN's free Morning Briefing.

“We have folks that can’t get a hand on any of them right now,” Saha said. “Hospitals want to do their part and want to expand access to testing, but they’re hamstrung by the fact that they can’t access the actual swabs.”

Former FDA commissioner Scott Gottlieb pointed out on Twitter on Monday that a lack of swabs could be the new bottleneck even as the number of sites with the capacity to test has increased, showcasing that the weakest link in the supply chain becomes the limiting factor.

Missouri has been among the places seeing a shortage of swabs, state Department of Health and Senior Services spokesperson Lisa Cox confirmed over the weekend. Ontario, Canada, plus counties in Washington and Michigan have announced that limitations on swabs were creating a logjam in their testing capabilities, according to news reports. Axios first reported on the national swab shortages last week.

Part of the problem lies in the nature of current test procedures for COVID-19. Typically, one needs to use two swabs per person: one swab for a flu test to potentially rule out the need for a coronavirus test, then another for the coronavirus if the flu test is negative.

Since the swabs are a product that is regulated, patented and specialized, they’re hard to make on the fly, Saha said. That puts additional pressure on the two largest manufacturers.

One of them, Puritan Medical Products, based in Guilford, Maine, has been working to keep up with demand even as its workforce, like many in America, has been affected by the spread of the virus, spokesperson Timothy Templet said.

The U.S. Department of Health and Human Services, along with working groups from the White House and other federal agencies, has been in discussion with the company over the past week to redirect some of their manufacturing capabilities away from other clients to COVID-19 specialty swab production, Templet said.

Currently, Templet estimated, Puritan is producing between 800,000 and a million swabs a week that could go to COVID-19 efforts. If the government decides to redirect its manufacturing efforts, cutting off the supply of its other medical products for items like flu kits, it could make millions more.

Still, Templet said that ramping up production so drastically would take a few weeks to get fully off the ground, considering manufacturing capabilities and protocols.

Templet said HHS plans to open 37 testing sites across the country in the coming days to account for increased testing needs — which will require even more specialty swabs. He also said the government is considering expanding its recommended testing material options to allow for more general nasal swabs to keep up with the increased testing demand.

FDA spokesperson Stephanie Caccomo said in an email that the agency is aware of “supply chain pressures on obtaining certain materials for running tests” and that it is continuing to evaluate other options for specimen collection supplies, which it will list on its website.

Another specialty swab manufacturer, Copan Diagnostics Inc., which is based in the Lombardy region of northern Italy, is working 24/7 in a “tremendous effort” to produce products such as its CDC-recommended and patent-protected FLOQSwabs, all while asking customers and distributors to ration orders to maximize output, spokesperson Gabriela Franco said in an email.

While produced in a region hit hard by the novel coronavirus, where most other work has stopped, Franco said, the Italian government has allowed the business to continue production. And it is working with local and national authorities on keeping production up in case stricter health restrictions are adopted.

Copan could produce 720,000 specialized swabs in a day and as many as 100 million per year for the global market, according to records the firm filed in a 2018 patent lawsuit.

Amid the crunch, Copan CEO Stefania Triva said in an emailed statement that her company is working round-the-clock to keep up with demand.

“Without full commitment and sacrifices from all of my staff, we would not be able to meet this unexpected demand,” Triva said. “COPAN’s more than 660 members of staff, many of whom are women, without hesitation, once made aware of the Coronavirus emergency, have stepped up from five working days and two shifts to seven working days and night shifts also.”

The volume of Copan swabs arriving in the U.S. has been increasing, according to data from Import Genius, which tracks container ships arriving in American ports. Six tons of Copan culture swabs arrived at the port of Norfolk, Virginia, on March 4. Before that, 4.5 tons of swabs arrived at the same port on Jan. 20. The swabs then tend to go to domestic test-kit assemblers that package them for health care use.

New Jersey-based Becton, Dickinson and Co., a leading assembler of those kits involved in ramping up coronavirus testing, has seen extremely high demand for swab products this year, company spokesperson Troy Kirkpatrick said. But now that Copan is “running operations 24/7” to increase production, Kirkpatrick said, “we will be providing hundreds of thousands of swabs to the U.S. market each week.”

We encourage organizations to republish our content, free of charge. Here’s what we ask:

You must credit us as the original publisher, with a hyperlink to our khn.org site. If possible, please include the original author(s) and “Kaiser Health News” in the byline. Please preserve the hyperlinks in the story.

It’s important to note, not everything on khn.org is available for republishing. If a story is labeled “All Rights Reserved,” we cannot grant permission to republish that item.

Have questions? Let us know at KHNHelp@kff.org

Many Preventive Medical Services Cost Patients Nothing. Will a Texas Court Decision Change That?

Hospitals Divert Primary Care Patients to Health Center ‘Look-Alikes’ to Boost Finances

Children in Northern California Learn to Cope With Wildfire Trauma

Patient Satisfaction Surveys Earn a Zero on Tracking Whether Hospitals Deliver Culturally Competent Care

© 2022 Kaiser Family Foundation. All rights reserved.

Thank you for your interest in supporting Kaiser Health News (KHN), the nation’s leading nonprofit newsroom focused on health and health policy. We distribute our journalism for free and without advertising through media partners of all sizes and in communities large and small. We appreciate all forms of engagement from our readers and listeners, and welcome your support.

KHN is an editorially independent program of KFF (Kaiser Family Foundation). You can support KHN by making a contribution to KFF, a non-profit charitable organization that is not associated with Kaiser Permanente.

Click the button below to go to KFF’s donation page which will provide more information and FAQs. Thank you!